Table 1.

Expression of CRH mRNA during development

Developmental age	Brain area
Developmental age	Thalamus	PVN	Amygdala	Caudate/putamen	Frontal cortex	Hippocampus
E12	n.i.	n.i.	n.i.	0.70 ± 0.49	n.i.	n.i.
E15	0.79 ± 0.26	1.58 ± 0.95	n.i.	12.36 ± 1.41^***	n.i.	n.i.
P1	0.90 ± 0.11	4.98 ± 2.74	12.46 ± 2.18^**	25.98 ± 3.17^***	10.27 ± 2.32^*	0.35 ± 1.07
P3	0.68 ± 0.32	0.74 ± 0.11	19.00 ± 2.15^***	33.86 ± 3.17^***	11.64 ± 0.31^***	1.67 ± 0.50
P7	0.74 ± 0.30	1.55 ± 0.62	5.37 ± 0.37^***	7.11 ± 0.81^**	3.84 ± 0.23^**	3.76 ± 1.54
P14	0.68 ± 0.16	0.19 ± 0.07	9.64 ± 2.20^*	11.05 ± 1.95^**	9.03 ± 1.13^**	3.36 ± 0.81^*

Values are reported as mean ± SEM for FBCRHOE mRNA fold change over control^dev signal. Mice were analyzed at E12, E15, P1, P3, P7, and P14. All mice were off doxycycline. Overexpression of CRH likely occurs between E12 and E15. n.i., Not identifiable.
↵*p ≤ 0.05;
↵**p ≤ 0.01;
↵***p ≤ 0.001 compared to control^dev; Student's t test.